Clinical Research in Solid Tumors (CREST)

Ernest Nadal / Josep M. Piulats

PRINCIPAL INVESTIGATORS
  • Margarita Garcia Martin
  • Berta Laquente Saez
  • Mariona Calvo Campos
  • Maria Del Carmen Galan Guzman
  • Ramon Palmero Sanchez
  • Maria Jové Casulleras
CLINICAL RESEARCHERS
  • Noelia Vilariño Quintela
  • Mar Marín Melià
POSTDOCTORAL RESEARCHERS (R2)
  • Elisabeth Aliagas Marín
  • Mireia Gausachs Romero
PREDOCTORAL RESEARCHERS (R1)
  • Valentin Navarro Perez
SCIENTIFIC SUPPORT
  • Maite Encuentra Marti
  • Xavi Pérez Martín
  • Marina Figuerola Sans
MANAGEMENT SUPPORT
  • Carles Codony Servat
Cancer
Oncobell

Scientific production

36

PAPERS

12 PUBLICATIONS IN FIRST DECILE

25 PUBLICATIONS IN FIRST QUARTILE

Selected publications

  • Serra O., Galán M., Ginesta M., Calvo M., Sala N., Salazar R.. Comparison and applicability of molecular classifications for gastric cancer. CANCER TREATMENT REVIEWS. 10.1016/j.ctrv.2019.05.005
  • Castet F, Garcia-Mulero S, Sanz-Pamplona R, Cuellar A, Casanovas O, Caminal JM, Piulats JM . Uveal Melanoma, Angiogenesis and Immunotherapy, Is There Any Hope?. CANCERS. 10.3390/cancers11060834
  • Ponce S., Bruna J., Juan O., López R., Navarro A., Ortega A., Puente J., Verger E., Bartolomé A., Nadal E.. Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases. CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY. 10.1016/j.critrevonc.2019.03.017
  • Jove M., Spencer J., Clench M., Loadman P., Twelves C.. Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 10.1016/j.critrevonc.2019.06.008
  • Nadal E, Massuti B, Dómine M, García-Campelo R, Cobo M, Felip E . Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors.. CANCER IMMUNOLOGY AND IMMUNOTHERAPY. 10.1007/s00262-019-02310-2

Research highlights

PROJECTS

7 Ongoing projects
2 Started projects 

 

118 Ongoing clinical trials
35 Started clinical trials

PUBLISHED WORKS

1 Clinical guideline

Selected projects

  • Estudio de Nuevas Estrategias Terapéuticas en Mesotelioma Pleural Maligno y de la Heterogeneidad Clonal y de la Evolución Temporal a Nivel Genómico (1/1/2019 – 31/12/2021) PI: NADAL ALFORJA, ERNEST. Funder: FIS-Instituto de Salud Carlos III.
  • Caracterización germinal y somática del cáncer de pulmón en pacientes jóvenes (Early Onset LUNG Cancer, EOLUNG) (15/11/2019 – 14/11/2021) PI: NADAL ALFORJA, ERNEST. Funder: SEOM.
  • Estudio del efecto del sistema inmune sobre el crecimiento de carcinomas de endometrio con fenotipo hiper/ultra mutado in vivo. (1/1/2018 – 31/12/2020) PI: PIULATS RODRIGUEZ, JOSEP MARIA. Funder: FIS-Instituto de Salud Carlos III.
  • Càncer de pulmó en poblacions especials (1/3/2018 – 31/12/2019) PI: NADAL ALFORJA, ERNEST. Funder: DEPARTAMENT SALUT (PR).
  • A phase II single-arm study to investigate Tepotinib combined with Osimertinib in met amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating egfr mutations and having acquired resistance to prior 1st to 3rd generation EGFR-tyrosine kinase inhibitor therapy (30/12/2019
    – ) PI: NADAL ALFORJA, ERNEST. Funder ref.: MS200095-0031.
  • A phase 2, open-label, single-arm trial of Trastuzumab Deruxtecan (DS-8201A) in HER2-positive, unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma subjects who have progressed on or after a Trastuzumab-containing regimen (19/11/2019 – ) PI: CALVO CAMPOS, MARIONA. Funder ref.: DS8201-A-U205.
  • Ironman-es: estudio prospectivo observacional de parámetros clínicos y biomarcadores en cáncer de próstata avanzado en hospitales de España (5/11/2019 – ) PI: PIULATS RODRIGUEZ, JOSEP MARIA. Funder ref.: IRONMAN-ES (CNI-OLA-2019-01).
  • A multicenter, double blind, randomized, controlled study of M7824 with concurrent chemoradiation followed by M7824 versus concurrent chemoraditation plus placebo followed by Durvalumab in participants with unresectable stage iii non-small cell lung cancer (8/10/2019 – 8/10/2020) PI: NADAL ALFORJA, ERNEST. Funder ref.: MS200647-0005.
  • Ensayo fase III, internacional, multicéntrico, doble ciego, aleatorizado y controlado con placebo de Durvalumab tras el tratamienteo con radioterapia estereotáctica corporal (SBRT), para el tratamiento de pacientes con cáncer de pulmón no microcítico, estadio I/II no secado, con ganglios linfáticos negativos (PACIFIC-4) (13/9/2019 – ) PI: NADAL ALFORJA, ERNEST. Funder ref.: D9103C00001 (PACIFIC-4).